17 results about "Positive inotropism" patented technology

The invention relates to the technical field of physiological parameter monitoring, in particular to a construction method of a cardiology rehabilitation evaluation model, which comprises the following steps: monitoring a systolic pressure peak value, a diastolic pressure valley value and duration time of a postoperative patient, constructing a waveform parameter set, calculating a peak sequence amplitude change rate through a moving average method, and calculating a peak sequence amplitude change rate. Marking a form abnormal period and a structure drift region; dividing an active phase and a passive phase to extract wave crest characteristics; analyzing time sequence difference to generate a three-dimensional rhythm vector; constructing a regression model; according to the method, heart pressure change is continuously monitored, a waveform structure is identified, compression period change is dynamically captured, a structure drift area is determined and positioned by combining an amplitude change rate and a difference value, multi-dimensional heart rhythm characteristics are extracted, day and night differences are analyzed, and multi-day deviation values are integrated to generate a scoring system; the abnormal recognition, rhythm quantification and trend prediction capabilities are improved, and a high-adaptability quantification basis is provided for rehabilitation evaluation.

This invention belongs to the field of biomedical technology, specifically involving Trmt61a The application of genes in the preparation of drugs for treating pathological myocardial hypertrophy. This invention provides... Trmt61a The application of genes in the preparation of drugs for treating pathological myocardial hypertrophy, the aforementioned Trmt61a The nucleotide sequence of the gene is shown in SEQ ID NO.1. Animal experiments have shown that knocking down... Trmt61a Gene knockdown can significantly improve cardiac contractile function after aortic arch coarctation surgery, alleviate cardiomyocyte hypertrophy, reduce the degree of cardiac fibrosis, and effectively treat pathological myocardial hypertrophy. This invention is the first to demonstrate knockdown... Trmt61a Genes can effectively improve pathological myocardial hypertrophy, providing a new drug development path and target for the prevention and treatment of this disease, and have important medicinal value and clinical application prospects.

The invention provides application of a reagent for intervening circ-ZNF609 expression in preparation of a medicine for preventing and / or treating cardiac hypertrophy, and belongs to the technical field of biological medicine. The invention provides application of a reagent for intervening circ-ZNF609 expression in preparation of a medicine for preventing and / or treating cardiac hypertrophy. According to the invention, an adeno-associated virus delivery system is utilized to deliver a reagent targeting circ-ZNF609 into cardiac muscle tissues to interfere the expression of circ-ZNF609, so that cardiomyopathy hypertrophy can be inhibited, the cardiac contraction function can be improved, and pathological ventricular remodeling caused by pressure overload can be resisted at the same time. Therefore, the invention provides a new way for treating cardiac hypertrophy.

The present invention belongs to the field of biomedicine technology, and specifically relates to a circSamd4 and its use in the preparation of a drug for treating myocardial fibrosis. In order to screen and obtain circRNA that plays a key role in the process of myocardial fibrosis, so as to provide a drug for preparing myocardial fibrosis, the present invention provides a circSamd4, a vector for reducing the expression of circSamd4, a host cell containing the vector and its use in the preparation of a drug for treating myocardial fibrosis. The present invention discovered for the first time a circSamd4 that plays a key role in the process of myocardial fibrosis, the nucleotide sequence of which is shown in SEQ ID NO: 1 or SEQ ID NO: 2, and verified that knocking down circSamd4 expression can improve the impaired cardiac contractile function caused by thoracic aortic arch stenosis for 4 weeks, reduce myocardial fibrosis, and inhibit the activation of myocardial fibroblasts. It can be used to prepare a drug for treating myocardial fibrosis, and has important practical significance.

The invention belongs to the technical field of biological medicines, and particularly relates to an application of a Fam198B gene or a protein coded by the Fam198B gene in preparation of a medicine for preventing, relieving or / and treating myocardial infarction. It is found for the first time that the expression level of Fam198B in myocardial tissue of a myocardial infarction mouse induced by coronary artery ligation is remarkably increased; in addition, after myocardial infarction of the mouse with the Fam198B gene specifically knocked out of the myocardial cells is carried out for one day, the myocardial cell apoptosis is obviously increased, and the systolic function of the heart becomes poor; after 10 days of myocardial infarction of the mouse with the Fam198B gene specifically knocked out of the myocardial fibroblasts, the systolic function of the heart becomes poor, collagen secretion of the fibroblasts is increased, and the death rate of the mouse is remarkably increased. The results show that Fam198B participates in dual regulation and control of myocardial cell survival and fibroblast activation, and plays a role in heart protection in the pathological process of myocardial infarction. Therefore, the Fam198B gene, the Fam198B protein and the activator expressed by the Fam198B gene can be used for preparing the medicine for preventing, relieving or / and treating the myocardial infarction, and the Fam198B gene or the Fam198B protein can also be used as a medicine target for screening the medicine for preventing, relieving or / and treating the myocardial infarction.

The invention provides a traditional Chinese medicine composition for treating heart failure and a preparation method of the traditional Chinese medicine composition. The traditional Chinese medicine composition is prepared from the following components: 1-12 parts of rohdea japonica, 1-12 parts of codonopsis pilosula, 1-12 parts of astragalus membranaceus, 1-12 parts of cassia twig, 1-8 parts of bighead atractylodes rhizome, 1-12 parts of poria cocos, 1-12 parts of radix ophiopogonis, 2-14 parts of semen lepidii, 1-10 parts of radix aconiti lateralis preparata, 1-10 parts of schisandra chinensis, 1-12 parts of hairyvein agrimony, 1-10 parts of pseudo-ginseng, 1-12 parts of epimedium, 1-12 parts of leonurus, 1-10 parts of ligusticum wallichii, 2-14 parts of salvia miltiorrhiza, 2-12 parts of radix sophorae flavescentis and 1-8 parts of liquorice. The traditional Chinese medicine composition can enhance myocardial contractility, increase coronary artery blood flow volume, protect myocardial cells, improve heart functions, obviously improve the heart functions and left ventricular remodeling, discharge liquid retained at the time of heart failure, relieve the pre-load of the heart and relieve edema; load during cardiac contraction is reduced, and excessive work of the heart is avoided.

The invention relates to application of a USP18 gene as a drug target in screening drugs for preventing, relieving and / or treating myocardial ischemia-reperfusion injury. Compared with a mouse without the USP18 gene knockout, the mouse with the USP18 gene knockout has the advantages that the myocardial infarction area is obviously reduced, the mitochondrial dysfunction is obviously improved, the cardiac contraction function is obviously enhanced, and the long-term myocardial fibrosis degree is reduced. The result shows that USP18 gene knockout can significantly alleviate the pathological process of myocardial ischemia reperfusion injury. Therefore, the USP18 gene is used as a target, and the screened USP18 gene expression inhibitor can be used for preparing medicines for preventing, relieving and / or treating myocardial ischemia-reperfusion injury. Compared with an Anti-NC mouse, the myocardial infarction area of the Anti-PTEN-L mouse is remarkably reduced, the mitochondrial dysfunction is remarkably improved, the cardiac contraction function is remarkably enhanced, and the long-term myocardial fibrosis degree is reduced. Therefore, the PTEN-L neutralizing antibody can also be used for preparing the medicine for preventing, relieving and / or treating the myocardial ischemia-reperfusion injury.

The present invention relates to the field of biomedicine and provides an application of an EP3 receptor antagonist L-798106 in the preparation of a drug for preventing myocardial ischemia-reperfusion injury. After long-term research, the present invention unexpectedly found that L-798106 can significantly reduce the myocardial infarction area and reduce the serum myocardial enzyme spectrum levels in mice after myocardial ischemia-reperfusion surgery, improve cardiac contractile function, and alleviate myocardial ischemia-reperfusion injury. The results of the present invention provide a theoretical basis for L-798106 to improve myocardial ischemia-reperfusion injury, and in particular provide a foundation for the research and development of related drugs. In summary, the present invention has found that the EP3 receptor antagonist L-798106 can be used to prevent and treat diseases related to myocardial ischemia-reperfusion injury, and has clinical research and development value.

The present invention relates to systems and methods for monitoring impedance from a sensor in the chest of a subject to determine the status of lung inflation or presence of pneumothorax in the subject, the presence of pulmonary edema, the status of regional lung ventilation, and the status of cardiac contractility.

The present invention discloses the use of RAB31 in preparing a product for preventing and / or treating hypertension. The present invention finds that inhibiting the expression of the RAB31 gene can significantly inhibit the increase in blood pressure of mice after AngII stimulation, inhibit the increase in the thickness of the abdominal aorta media, inhibit the increase in the pulse wave propagation velocity, inhibit cardiac systolic dysfunction, and reduce hypertension, indicating that RAB31 is a new target or new treatment strategy for studying hypertension.

Provided is an implantable heart failure treatment device, including a housing; an anchoring member, connected to the housing and fixing the housing to a heart; a pair of stimulation electrodes coupled to the housing, configured to be in contact with a predetermined stimulation position of the heart, and configured to apply an electrical stimulation pulse for enhancing cardiac contractility to the predetermined stimulation position; a pulse generation module accommodated within the housing, electrically coupled to the stimulation electrodes, and configured to generate the electrical stimulation pulse; and a control module accommodated within the housing, electrically coupled to the stimulation electrodes and the pulse generation module, and configured to: receive a far-field sense signal indicating a global excitation event of the heart of a patient and a local sense signal indicating a local excitation event of a local position of the heart of the patient; and determine, at least based on the far-field sense signal and the local sense signal, whether the local excitation event of the local position of the heart of the patient corresponds to a specific global excitation event, and transmit the electrical stimulation pulse to the stimulation electrodes in an absolute refractory period of the local excitation event.

The present invention discloses the application of DNAJC9 in the preparation of drugs for treating heart failure, recombinant vectors and drugs for treating heart failure, and belongs to the field of biomedicine technology. The present invention provides the application of DNAJC9 protein in the preparation of drugs for treating heart failure, using the coding gene containing the DNAJC9 protein as a recombinant vector, and when the circular vector of the recombinant vector is an AAV overexpression vector, it also includes adeno-associated virus packaging. The present invention proves that the drugs for treating heart failure prepared by DNAJC9 can treat or improve heart failure, especially have a good therapeutic effect on heart failure caused by ischemia-reperfusion injury; specifically, DNAJC9 has the effect of improving cardiac contractile dysfunction caused by myocardial ischemia-reperfusion injury for 3 weeks; overexpression of DNAJC9 can inhibit myocardial cell apoptosis induced by oxygen-glucose deprivation / recovery.

The invention relates to the technical field of biological medicines, in particular to application of an insulin-like growth factor 2 receptor IGF2R inhibitor in preparation of a medicine for preventing and / or treating fulminant myocarditis. The result of the embodiment of the invention shows that the IGF2R expression of the heart tissue is abnormally increased in the state of fulminating myocarditis, and is more obvious in myocardial cells. Expression and / or related biological functions of IGF2R are / is inhibited in a myocardial cell specific mode, the survival outcome of an animal model with fulminating myocarditis can be improved, the systolic and diastolic functions of the heart can be improved, myocardial damage markers are reduced, myocardial tissue inflammatory response is relieved, and the inflammatory factor level is reduced. The application disclosed by the invention is suitable for fulminating myocarditis types including but not limited to viral fulminating myocarditis, and a new intervention strategy and a potential drug target can be provided for the diseases.

The invention discloses an application of a water-soluble fullerene nano material in preparation of a medicine for treating and / or relieving heart failure. The treatment and / or relief of heart failure is embodied in at least one of the following aspects: 1) improving the systolic function of the heart; (2) the increase of the brain natriuretic peptide precursor content caused by heart failure is reduced; (3) the content of Ca < 2 + > in the failure heart is reduced; 4) improving cardiac hypertrophy caused by heart failure; 5) inhibiting cardiac fibrosis caused by heart failure; 6) reducing the active oxygen level of a heart pathologic region; 7) inhibiting inflammation of the heart failure part; and 8) inhibiting pyroptosis, apoptosis and cardiac fibrosis of the heart failure part. In a coronary artery ligation post-myocardial infarction heart failure mouse model, the FPs can regulate redox balance in a pathological area, reduce excessive inflammation, pyroptosis, apoptosis, cardiac hypertrophy and fibrosis of a heart failure part and improve a mouse cardiac systolic function, shows a good treatment effect, and is an ideal medicine for treating heart failure.

A heart phase-locked transcranial magnetic stimulation method and system based on heart-brain axis navigation positioning, the method comprising inputting a preprocessed electrocardiogram signal into a trained and converged TimeMixer model to output a predicted electrocardiogram waveform signal; splicing the predicted electrocardiogram waveform sequence and the original electrocardiogram waveform sequence to obtain a global electrocardiogram sequence, identifying effective R peaks and T wave peaks and determining T wave endpoints on the global electrocardiogram sequence; dividing the systole and diastole of the heart using the effective R peaks and the T wave endpoints, and assigning and encoding the systole and diastole of the heart; determining the target position of the transcranial magnetic stimulation according to the encoding labels corresponding to the systole and diastole of the heart and the transcranial magnetic stimulation target position determined by the heart-brain axis navigation mode, and controlling the parameters of the transcranial magnetic stimulation; by combining the electrocardiogram prediction of the TimeMixer model with the individualized stimulation target point determined by the heart-brain axis navigation, the problems of ignoring individual physiological state in the existing open-loop control, complex closed-loop acquisition being easily disturbed, and inaccurate target point positioning are solved.

The invention discloses application of triethylene tetramine in preparation of a medicine for treating or preventing sepsis complications. Researches show that triethylene tetramine (TETA) can reduce the cardiac systolic function caused by lipopolysaccharide (LPS), and the damage to the mitochondrial structure of myocardial tissue is improved to a certain extent; the TETA also shows that the TETA can improve alveolar interval thickening, pulmonary edema, increase of protein concentration and lactic dehydrogenase activity in alveolar lavage fluid, formation of inflammasome, pyroptosis and the like caused by the LPS to a certain extent; the triethylene tetramine can inhibit expression of inflammatory factors in myocardial tissue and lung tissue, the effect of the triethylene tetramine in treatment or prevention of sepsis complications (sepsis cardiomyopathy and sepsis acute lung injury) is indicated, a new treatment choice is provided for sepsis patients, and the triethylene tetramine has important clinical application value.